Nutex Health Inc.
No SEC Form 4 filings for $NUTX in the last 30 days.
See all $NUTX insider activity →Zacks.com highlighted four companies with strong net profit margins: Nutex Health (NUTX), RCM Technologies (RCMT), Remitly Global (RELY), and Belden (BDC). Each company's 2026 earnings estimates were revised upward, with NUTX up 32.5%, RCMT up 13.3%, RELY up 13.8%, and BDC up 5.7%. All companies recently beat earnings estimates.
Nutex Health (NASDAQ: NUTX) commented on a Fifth Circuit ruling invalidating federal QPA calculation rules under the No Surprises Act, which the company says artificially deflated payments. The court ruled insurers cannot include non-negotiated 'ghost rates' and must include bonus payments in QPA calculations. Nutex Health expects this to lead to fairer upfront payments for providers. The ruling may impact the company's financials, but the timeline for new regulations is uncertain.
Nutex Health Inc. (NASDAQ: NUTX) opened its 28th hospital, West Little Rock Emergency Hospital, and its third Arkansas facility. The 18,966-square-foot site at 17810 Chenal Parkway has eight ER beds, five inpatient suites, two triage rooms, and full lab and imaging (MRI, CT, X-ray, ultrasound).
Over the past 7 days, alphai's AI scored 2 news stories mentioning NUTX (Nutex Health Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent NUTX coverage spans earnings, regulation and financial news.
Upward earnings estimate may boost investor sentiment.
The court decision may increase future reimbursements for Nutex by removing ghost rates and requiring inclusion of bonus payments in QPA calculations.
The facility opening is a growth milestone that can support patient volumes and future revenue, but near-term financial impact is likely incremental.
Cost-structure reset from the HaloMD amendment and arbitration expense outlook likely supports margin expansion despite softer top-line.
Profitability jumped sharply on lower IDR-related contract services costs and stronger hospital visit volumes, with prospective margin tailwinds.
alphai scores every news story that mentions NUTX with an AI model for sentiment and relevance, and aggregates insider trades from Nutex Health Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zacks.com highlighted four companies with strong net profit margins: Nutex Health (NUTX), RCM Technologies (RCMT), Remitly Global (RELY), and Belden (BDC). Each company's 2026 earnings estimates were revised upward, with NUTX up 32.5%, RCMT up 13.3%, RELY up 13.8%, and BDC up 5.7%. All companies recently beat earnings estimates.
2 min readNutex Health (NASDAQ: NUTX) commented on a Fifth Circuit ruling invalidating federal QPA calculation rules under the No Surprises Act, which the company says artificially deflated payments. The court ruled insurers cannot include non-negotiated 'ghost rates' and must include bonus payments in QPA calculations. Nutex Health expects this to lead to fairer upfront payments for providers. The ruling may impact the company's financials, but the timeline for new regulations is uncertain.
2 min readNutex Health Inc. (NASDAQ: NUTX) opened its 28th hospital, West Little Rock Emergency Hospital, and its third Arkansas facility. The 18,966-square-foot site at 17810 Chenal Parkway has eight ER beds, five inpatient suites, two triage rooms, and full lab and imaging (MRI, CT, X-ray, ultrasound).
3 min readNutex Health (NUTX) reported Q2 2026 results on an earnings call. Total revenue fell to $210.8M from $244.0M. Net income rose to $65.8M, diluted EPS to $9.38, and adjusted EBITDA to $90.0M. Management cited lower contract services costs from a HaloMD amendment and higher patient visits, plus a hospital expansion pipeline.
7 min readNutex Health (NUTX) reported Q2 2026 results, with net income of $65.8M and diluted EPS of $9.38, versus a net loss of $17.7M a year earlier. Revenue fell 13.6% to $210.8M. The company cited IDR-related cost reductions, including a $52.3M contract services expense decline, and expects normalized historical expenses to drop 25% to 30% prospectively. Shares rose 14.88% to $186.19.
4 min readNutex Health Inc. (NASDAQ: NUTX) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income attributable rose to $65.8M (diluted EPS $9.38) for Q2, versus a loss in 2025. Six-month net income was $112.6M (EPS $15.87). Revenue fell to $427.2M for six months. Operating cash flow was $109.7M. Hospital visits increased.
6 min readNutex Health Inc. (NUTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2026. Nutex Health is a physi
7 min readNutex Health Inc. (NUTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. nutx-20260715 0001479681 FALSE 0001479681 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
4 min readThe article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
7 min readSTAT reports some for-profit ER operators are opting out of Medicare, which can exempt them from EMTALA’s requirement to screen and stabilize all arrivals. Houston-based Nutex Health, which runs 27 hospitals in 12 states, reportedly declines Medicare at most sites. Patients allege payment demands before exams; Nutex denies. STAT says Nutex revenue rose to $875M in 2025.
6 min read
